Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Les nouveaux critères de la Maladie d'Alzheimer - Perspective gériatrique.

Molin P, Rockwood K.

Can Geriatr J. 2016 Jun 29;19(2):74-82. doi: 10.5770/cgj.19.242. French. No abstract available.

2.

The New Criteria for Alzheimer's Disease - Implications for Geriatricians.

Molin P, Rockwood K.

Can Geriatr J. 2016 Jun 29;19(2):66-73. doi: 10.5770/cgj.19.207.

3.

Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease.

Roostaei T, Nazeri A, Felsky D, De Jager PL, Schneider JA, Pollock BG, Bennett DA, Voineskos AN; Alzheimer’s Disease Neuroimaging Initiative (ADNI)..

Mol Psychiatry. 2017 Feb;22(2):287-295. doi: 10.1038/mp.2016.35.

4.

Epidemiological pathology of Tau in the ageing brain: application of staging for neuropil threads (BrainNet Europe protocol) to the MRC cognitive function and ageing brain study.

Wharton SB, Minett T, Drew D, Forster G, Matthews F, Brayne C, Ince PG; MRC Cognitive Function and Ageing Neuropathology Study Group..

Acta Neuropathol Commun. 2016 Feb 8;4:11. doi: 10.1186/s40478-016-0275-x.

5.

Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment.

Mufson EJ, Malek-Ahmadi M, Perez SE, Chen K.

Neurobiol Aging. 2016 Jan;37:147-53. doi: 10.1016/j.neurobiolaging.2015.10.012.

6.

Brain-derived neurotrophic factor and TrkB expression in the "oldest-old," the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta.

Michalski B, Corrada MM, Kawas CH, Fahnestock M.

Neurobiol Aging. 2015 Dec;36(12):3130-9. doi: 10.1016/j.neurobiolaging.2015.08.022.

7.

Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects.

Zhao W, Wang J, Varghese M, Ho L, Mazzola P, Haroutunian V, Katsel PL, Gibson GE, Levine S, Dubner L, Pasinetti GM.

Neuropsychiatr Dis Treat. 2015 Mar 5;11:565-74. doi: 10.2147/NDT.S74898.

8.

PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.

Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR Jr, Jicha GA, Knopman DS, Kovacs GG, Mackenzie IR, Masliah E, Montine TJ, Nelson PT, Schmitt F, Schneider JA, Serrano-Pozo A, Thal DR, Toledo JB, Trojanowski JQ, Troncoso JC, Vonsattel JP, Wisniewski T.

Acta Neuropathol. 2015 May;129(5):757-62. doi: 10.1007/s00401-015-1407-2. No abstract available.

9.

Preventing Alzheimer's disease by means of natural selection.

Demetrius LA, Driver JA.

J R Soc Interface. 2015 Jan 6;12(102):20140919. Review.

10.

A neuronal DNA damage response is detected at the earliest stages of Alzheimer's neuropathology and correlates with cognitive impairment in the Medical Research Council's Cognitive Function and Ageing Study ageing brain cohort.

Simpson JE, Ince PG, Matthews FE, Shaw PJ, Heath PR, Brayne C, Garwood C, Higginbottom A, Wharton SB; MRC Cognitive Function and Ageing Neuropathology Study Group..

Neuropathol Appl Neurobiol. 2015 Jun;41(4):483-96. doi: 10.1111/nan.12202.

11.

Quantitative neuropathological assessment to investigate cerebral multi-morbidity.

Attems J, Neltner JH, Nelson PT.

Alzheimers Res Ther. 2014 Nov 28;6(9):85. doi: 10.1186/s13195-014-0085-y.

12.

Cerebral white matter hyperintensities in the prediction of cognitive decline and incident dementia.

Mortamais M, Artero S, Ritchie K.

Int Rev Psychiatry. 2013 Dec;25(6):686-98. doi: 10.3109/09540261.2013.838151. Review.

13.

Is synaptic loss a unique hallmark of Alzheimer's disease?

Scheff SW, Neltner JH, Nelson PT.

Biochem Pharmacol. 2014 Apr 15;88(4):517-28. doi: 10.1016/j.bcp.2013.12.028. Review.

14.

Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition.

Negash S, Wilson RS, Leurgans SE, Wolk DA, Schneider JA, Buchman AS, Bennett DA, Arnold SE.

Curr Alzheimer Res. 2013 Oct;10(8):844-51.

15.

Cognitive decline and dementia in the oldest-old.

Kravitz E, Schmeidler J, Beeri MS.

Rambam Maimonides Med J. 2012 Oct 31;3(4):e0026. doi: 10.5041/RMMJ.10092.

16.

Cell cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer's disease [corrected].

Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V.

PLoS One. 2013 Jul 5;8(7):e68361. doi: 10.1371/journal.pone.0068361. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/59ecb64c-1f53-4d8a-903c-2f835e78bd13.

17.

Dementia in the oldest old: a multi-factorial and growing public health issue.

Gardner RC, Valcour V, Yaffe K.

Alzheimers Res Ther. 2013 Jul 1;5(4):27. doi: 10.1186/alzrt181. Review.

18.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects.

Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, Rosario BL, Lopresti BJ, Saxton JA, Aizenstein HJ, McDade EM, Kamboh MI, DeKosky ST, Lopez OL.

Ann Neurol. 2013 Jun;73(6):751-61. doi: 10.1002/ana.23797.

19.

Neural restrictive silencer factor and choline acetyltransferase expression in cerebral tissue of Alzheimer's Disease patients: A pilot study.

González-Castañeda RE, Sánchez-González VJ, Flores-Soto M, Vázquez-Camacho G, Macías-Islas MA, Ortiz GG.

Genet Mol Biol. 2013 Mar;36(1):28-36. doi: 10.1590/S1415-47572013000100005.

20.

Neuropathologic basis of age-associated brain atrophy.

Erten-Lyons D, Dodge HH, Woltjer R, Silbert LC, Howieson DB, Kramer P, Kaye JA.

JAMA Neurol. 2013 May;70(5):616-22. doi: 10.1001/jamaneurol.2013.1957.

Items per page

Supplemental Content

Support Center